Please login to the form below

Not currently logged in
Email:
Password:

Loxo

This page shows the latest Loxo news and features for those working in and with pharma, biotech and healthcare.

Roche undercuts price of Bayer cancer drug after winning FDA approval

Roche undercuts price of Bayer cancer drug after winning FDA approval

Vitrakvi, which Bayer acquired from Loxo Oncology, won approval in patients with NTRK gene fusions in November.

Latest news

More from news
Approximately 6 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    This is the first US product approval for Loxo Oncology and its marketing partner Bayer, becoming the second company to get FDA backing for a drug that treats cancer based on ... NTRK fusions are rare – Loxo estimates that there are around 2, 500 to 3,

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    also extending to targeted cancer drugs, with Loxo Oncology and Bayer’s larotrectinib filed for TRK gene fusion tumours and due for an FDA verdict in November.

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    485. Array BioPharma / Loxo Oncology. Multi-year licence and collaboration. Drug candidate (preclinical) discovery of small molecule drugs for oncology targets.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics